Depth bar: Due-diligence dossier for Band A outreach. Estimates marked [~]; directory facts [dir]; unverified claims [!]. Never invent bill numbers, court outcomes, or emails.

1. Company overview & snapshot

Axa Parenterals Limited, founded 2005 by Krishan Kumar, is a Roorkee/Haridwar-belt sterile manufacturer of IV fluids and large/small volume parenterals (eye/ear/nasal drops, respules, injectables) using Rommelag / Weiler blow-fill-seal technology. CRISIL Nov 2025 reaffirms Crisil A-/Stable; FY25 revenue ₹230 Cr, FY26 guidance ₹270–300 Cr; consolidates Heilsa Life Sciences Pvt Ltd (vials, emulsions, liposomal, lyophilised, PFS/ampoules — propofol, enoxaparin, etc.). Company materials cite ~145k–280k sq.ft facilities, four FFS machines (2 LVP / 2 SVP), WHO-GMP / PIC/S orientation, exports to 60+ countries, CDMO for Cipla, Biocon, Abbott, Intas and peers. SIDCUL Haridwar Plot 34 Sector 8A also appears in lead reports — qualify which site holds the primary HT. Primary engineering contact in kit: Mohanakrishnan R, Sr Manager Projects & Engineering.

1.1 Legal identity & corporate structure

Axa Parenterals Ltd + Heilsa subsidiary with corporate undertaking (CRISIL consolidation). Confirm GSTIN/UPCL account for Kishanpur–Jamalpur Roorkee plant vs SIDCUL Haridwar plot. Promoter continuity: confirm Krishan Kumar current status (some directories say late — treat carefully; do not assert death without MCA). IndiaMart lists other executives (Sorabh Sinha etc.) — verify.

1.2 What they make & where money comes from

Sterile BFS IV fluids & SVP; Heilsa premium injectables. Contract manufacturing + own marks. Energy intensity among highest in cluster due to cleanrooms + sterilisation + BFS utilities.

1.3 Plants, addresses & footprint

Primary working pilot: Puhana Chowk, Vill. Kishanpur–Jamalpur, Roorkee/Haridwar Dist. ~247667–247669. Secondary listing: Plot 34, Sector 8A, IIE SIDCUL Haridwar 249403. Phone +91 7060067001 (CPHI). Choose the HT account with Rommelag lines.

1.4 Leadership & CRM map

Mohanakrishnan R — Projects & Engineering (primary). Sanjay Shrivastava — EVP (CPHI). Puneet Bhargava — GM. Promoter Krishan Kumar — economic. Heilsa leadership may own vials ramp energy separately — map early.

1.5 Recent news (24 months) & timing for Stamped

CRISIL 2025: premium vials/PFS validations; export accreditation mix rising; revenue CAGR ~14% over three years. Heilsa ramp is the energy timing story — new sterilisation/HVAC peaks.

2. Energy profile

DISCOM / supply (name early): UPCL for Roorkee/Haridwar industrial. Confirm circle (Haridwar vs Roorkee) on invoice.

2.1 Bill band, tariff & demand

₹230 Cr sterile BFS plant often ₹35–90 lakh/month HT [~] given continuous HVAC + autoclaves. CRISIL does not publish power line. Qualify; Band A gate critical because revenue is lower edge of Stamped Band A.

2.2 Generation, fuel & renewables

DG for sterile integrity during outages is mission-critical — poor DG vs grid decisions can dominate bills. Ask boiler/pure steam, chillers, WFI.

2.3 EnMS, PAT, ISO, BRSR

WHO-GMP focus; ISO 50001 not found. EU GMP applications noted on CPHI — inspection readiness may freeze OT; keep read-only.

2.4 Likely ₹ leak categories (hypothesis)

(1) HVAC vs sterilizer MD ownership across four Rommelag lines; (2) Heilsa validation peaks; (3) compressed air for BFS; (4) idle chiller staging; (5) DG runtime vs UPCL MD; (6) PF.

3. Operations, equipment & digital stack

3.1 Process flow & critical loads

Solution prep → filtration → BFS mould-fill-seal → sterilisation → packing → warehouse. Heilsa: vial/PFS/lyo trains. Critical: HVAC, pure steam/autoclaves, chillers, compressors, WFI.

3.2 Shifts, seasonality, production pattern

Near continuous sterile; batch sterilisation cycles create spikes. Normalise by bottles/vials.

3.3 Automation, metering, SCADA/EMS/DCS

Rommelag proprietary + plant utilities PLC. Path A with OEM boundaries respected.

3.4 Capex / tech projects affecting energy

Heilsa product validations and possible EU GMP-driven upgrades.

4. Stamped Energy fit analysis

4.1 ICP scorecard

Revenue ~₹230 Cr is Band A lower edge — bill ≥₹30L mandatory gate. Process intensity strong. Private — accessible.

4.2 Fit score rationale

Fit 8/10: sterile intensity excellence; bill gate and dual-address ambiguity are risks.

4.3 Wedge (parser-critical)

The strongest wedge is: four Rommelag BFS lines — whether HVAC hold or sterilisation cycles own UPCL maximum demand as Heilsa vials/PFS ramps — assign each avoidable coincidence a rupee owner and verify with evidence without touching BFS interlocks.

4.4 Objections & competitors

“Sterile quality freezes changes” → sequencing/idle only, no setpoint for Grade A. “Heilsa is separate” → map which meter. “We’re smaller than Akums” → intensity still clears bill gate if HT proves out.

4.5 Pilot design

Roorkee BFS campus one utilities feeder, 90 days spanning at least one sterilisation-heavy week. Kill if bill <₹30L.

5. Before you reach out

5.1 Discovery checklist

• Which address holds Rommelag HT (UPCL).
• ₹ lakh/month; DG runtime hours.
• HVAC vs autoclave submetering.
• Heilsa load on same bill?
• Mohanakrishnan + MD approver.
• Two bills + bottle output.
• EU GMP timeline constraints.

5.2 Do not lead with

• Do not lead with dashboards, AI buzzwords, generic ESG, or a promised percentage reduction presented as fact.
• Do not claim sterile process consulting.
• Do not confuse with AXA Insurance brand.
• Do not assert promoter status without MCA.
• Do not ignore bill gate because process looks heavy.

5.3 Opening hooks (email / call / WhatsApp)

“With four Rommelag lines, is HVAC or sterilisation owning your UPCL MD as Heilsa ramps — we sit read-only and put rupees on the answer.”

6. Risks, flags, controversies & sources

6.1 Integrity / controversy / regulatory (search explicitly)

• Bill gate: Revenue lower-Band-A — may fail ₹30L in off months.
• Address duality: Roorkee vs SIDCUL Haridwar.
• Litigation/PCB/labour: No Axa Parenterals-specific NGT closure or major lawsuit found in July 2026 search; watch UKPCB sterile industry cluster norms.
• CRISIL: A-/Stable is positive credit signal, not controversy.
• Search: Axa Parenterals / Heilsa Life Sciences + PCB, NGT, lawsuit, labour, FDA 2023–2026.

6.2 Data quality flags

• Dual plant listings.
• Bill estimate critical to validate.
• Email inferred.
• Promoter vital status uncertain in secondary web results — verify offline.

6.3 Sources consulted

• CRISIL Axa Parenterals Nov 2025 rationale.
• https://axaparenterals.com ; CPHI Online company profile.
• IndiaMart about page; Mohanakrishnan LinkedIn.
• Lead report UK gap July 2026.

Extended call-prep narrative (Stamped field use)

B1. First 20 minutes of discovery

Open with process respect, not software. Confirm legal entity on the invoice, DISCOM name, and who owns the largest feeder MD event in the last 90 days. Ask for two invoices and one production calendar export before any platform demo. If the champion cannot produce bills within a week, treat the opportunity as stalled — Bill Verification Program without invoices is theatre. Record whether Path A (historian/meter export) or Path B (CSV) is realistic given OT policy. Confirm the economic buyer who can approve a Rs 2–5 lakh [~] fixed 90-day fee without a full ERP tender.

B2. Prescription card discipline

Every recommendation must name: event, owner, due date, expected rupee line on the DISCOM invoice, operational constraint, and evidence of execution. Cards without owners are deleted. Cap weekly cards at five so plant teams are not flooded. Prefer MD sequencing and idle-hold cuts before exotic tariff products. Never propose changing validated recipe, membrane current, sterile pressure, or Tempcore quench parameters. If quality or safety forbids a schedule change, mark the lever as blocked and move on — credibility beats aggressive savings claims.

B3. Verifying savings without gaming

A lower bill alone is not success if tonnes, pairs, or batches fell. Normalise against a production proxy agreed in week 1. Document holidays, forced outages, new-line commissioning, captive/solar settlement changes, and weather-sensitive HVAC. Keep a decision ledger shared with the plant: recommendation, owner, status, expected vs observed invoice delta. Present kill or expand at day 90 with the same ledger — this is how Stamped differs from audit PDFs that never close.

B4. Competitive and incumbent handling

If the site has EMS/SCADA/BMS, OEM analytics, ISO consultants, or solar EPCs, congratulate the spend and ask what residual bill lines still surprise them monthly. Position Stamped as the closure layer: rupee assignments and invoice reconciliation. Refuse head-to-head dashboard bake-offs. If Gujarat, Panipat, or Noida corporate IT appears, keep plant electrical as the proof owner and let corporate rubber-stamp after a verified bill line — not before.

B5. Geographic and cluster logistics

Batch 3 spans Mandi Gobindgarh, Paonta/Derabassi/Rajpura, Ghaziabad/Muzaffarnagar, and Kanpur–Unnao. Plan field days by corridor. Carry printed one-pagers: Fit score, DISCOM hypothesis, strongest wedge sentence, and two discovery questions. After each visit, update extras field intel — especially corrected phones, electrical names, and whether the bill cleared Rs 30 lakh/month.

B6. Messaging hygiene for this batch

Owner-operated steel/leather accounts tolerate Hindi-friendly WhatsApp and short calls. Listed pharma/chemical accounts prefer email plus LinkedIn with technical depth. Never open with controversies (GST/Excise history, EuGMP observations, rating actions) — those are internal briefings only. Always name DISCOM early in research-backed prep sheets so call-prep UI can render correctly.

6.4 Evidence discipline and next research actions

This dossier separates three evidence classes. Verified public facts come from company websites, CRISIL/ICRA ratings, BSE/NSE filings, press releases, and named LinkedIn profiles. Directional operating hypotheses follow from disclosed process (press lines, dairy utilities, fryers, forging, pharma HVAC/BFS) and are not claims about a specific machine failure. Commercial estimates—especially monthly electricity bills—remain estimates until the site shares a current HT invoice and production context.

Practical sequence after first contact: (1) verify legal entity and invoice ownership; (2) collect two DISCOM invoices with tariff, demand and PF lines; (3) identify the top three load events with the electrical/utility owner; (4) map production constraints that cannot move; (5) agree the smallest controllable boundary for a 90-day trial. Calculate demand, energy, reactive/PF and tariff components separately. Normalise against strokes, litres, batches or tonnes. Record baseline dates, shutdowns, commissioning, fuel/captive changes and weather-sensitive HVAC. Keep a decision ledger: recommendation, owner, due date, constraint, expected ₹ line, evidence, invoice result.

Security: confirm historian export, meter CSV or supervised read-only access; retention; IT/OT roles. No proposal implies changing PLC logic, recipes, interlocks, setpoints or operator authority. Treat adverse information proportionately — a negative search is not a clearance; a regional NGT matter is not automatic guilt for an unrelated site.

7. Extended plant diligence notes (Batch 4 depth addendum)

7.1 Sterile BFS intensity

Four Rommelag/Weiler BFS lines with post-fill sterilisation create one of the toughest MD attribution problems in Uttarakhand pharma: continuous HVAC for aseptic zones plus cyclic autoclave/pure-steam loads. Operators may believe HVAC is “uncontrollable quality.” Stamped does not fight Grade A setpoints; it finds staging, concurrent steriliser runs, and idle compressor banks that QA will accept changing.

7.2 Heilsa ramp

CRISIL’s narrative on vials/PFS/premium products (propofol, enoxaparin, etc.) implies new clean utilities and validation peaks. Confirm whether Heilsa shares Axa’s UPCL account. If not, pick the account that already clears Rs 30 lakh/month. If shared, expect step-change mid-pilot and normalise.

7.3 Bill gate honesty

At Rs 230 Cr revenue, Axa is Band A process-rich but revenue-light versus Akums/NATCO. Some months may miss Rs 30L. Path B pricing readiness should be mentally prepared, but do not pre-discount before seeing invoices — sterile plants often clear the gate on HVAC alone.

7.4 Dual address

Roorkee Kishanpur-Jamalpur versus SIDCUL Plot 34 Sector 8A must be resolved on day one. CPHI phone +91 7060067001 should reach someone who knows which gate takes visitors for BFS lines.

7.5 Brand collision

“Axa” triggers insurance brand confusion in cold email subject lines. Prefer “Axa Parenterals Roorkee / Rommelag” in subjects. Never joke about the confusion in first touch — just be precise.

7.6 CRISIL A- as sales signal

A-/Stable rating and promoter experience narrative support budget capacity. Use as confidence, not as a credit deep-dive with the plant head.

8. Call-prep annex — Axa Parenterals Roorkee

8.1 Sixty-second plant story (memorise)

Axa runs four Rommelag/Weiler BFS lines for IV fluids and SVP at ~Rs 230 Cr FY25 (CRISIL A-/Stable), with Heilsa ramping vials/PFS. The sell is whether HVAC or sterilisation owns UPCL MD — read-only prescriptions, QA-safe, evidence-verified.

8.2 Bill-gate script (say it early)

“Our Band A programmes start when HT is about Rs 30 lakh a month or more — can we confirm with two recent UPCL bills before we scope engineering?” Saying this early earns respect and saves weeks.

8.3 Sample discovery questions (extra)

• Roorkee vs SIDCUL Haridwar — which has Rommelag?
• Heilsa on same consumer number?
• Autoclave count and typical cycle overlap?
• HVAC setbacks allowed in Class C/D during idle?
• DG kVA and monthly runtime hours?
• EU GMP audit timing?

8.4 CDMO customer constraints

Cipla/Biocon/Abbott campaigns may throttle change windows. Ask which customers are on which lines before proposing sequencing.

8.5 Mohanakrishnan as technical translator

His LVP/SVP projects background means he can explain BFS utilities better than sales. Let him talk; take notes; convert to Rs cards.

8.6 Path B readiness

If bill is Rs 20–29L consistently, switch to Path B language without drama. Process intensity still justifies a scoped engagement if MD volatility is high.

9a. Axa Roorkee-specific contingency notes

If bill gate fails, document sterilisation MD volatility — Path B may still make sense for a short scope. If Heilsa meter is separate and larger, redirect champion intro without ego. If EU GMP inspection is within 90 days, freeze prescriptions that require procedural changes; stick to leak/air/scheduling items QA already allows.

9. Scenario planning & commercial contingencies

9.1 Three scenario tree

Scenario A — Fast proof: Bill clears the Band A floor, champion shares two invoices in week one, and Path A data export works. Compress discovery, issue first prescription cards by day 14, chase a clear invoice line by day 75.

Scenario B — Slow politics: Champion is interested but corporate or QA freezes vendor onboarding. Keep a monthly nurture with one process-specific insight; do not burn the economic buyer. Re-open after a dated event (COD, ISO audit, season peak).

Scenario C — Bill gate fail: Site is process-fit but HT spend sits under Rs 30 lakh/month. Offer Path B only if volatility or MD pain is extreme; otherwise park with a reminder to revisit after expansion.

9.2 Red-team of the wedge

Ask: could a competent internal electrical team get 60% of the value with a spreadsheet? If yes, Stamped must emphasise continuity, WhatsApp assignment, and DISCOM verification friction they will not sustain manually. Ask: is the wedge dependent on a single charismatic champion? If yes, recruit a deputy owner in week two.

9.3 Documentation pack for MSA later

Keep: invoice redactions, consumer number, sanctioned demand, feeder sketch, champion org chart, data access memo, kill criteria signed in email, weekly prescription log. These become the audit trail when finance asks why software opex exists.

9.4 Ethics and claims discipline

Do not overstate early-deployment percentages as guarantees. Label estimates. Do not invent lawsuits. Do not use Apollo. Do not commit hardware. Do not imply PLC writes. If a press or pharma quality constraint blocks a prescription, document and skip — credibility compounds.

9.5 Local logistics

Plan travel clusters: Greater Noida Ecotech + YEIDA Jewar in one day; Lucknow Gudamba + PTC SMTC in one trip; Selaqui HAB + NATCO in one morning; Haridwar Themis + Roorkee Axa in one SIDCUL/Roorkee loop. Carry printed one-pagers without confidential third-party data.

10. Source critique & residual unknowns (Axa)

CRISIL November 2025 rationale is the best financial source (Rs 230 Cr FY25, A-/Stable, Heilsa consolidation). Website/CPHI confirm Rommelag/Weiler positioning and export footprint. Residual unknowns: which physical address holds the BFS HT account, monthly bill vs Rs 30L gate, promoter current status, and Heilsa meter topology. IndiaMart executive names need confirmation. Because revenue sits at Band A floor, invoice proof is the single highest-value next artefact — prioritise that over more web research.

11. Stamped operating principles for this account

Stay plant-first. Prefer one feeder over campus mythology. Prefer WhatsApp-assigned prescriptions over dashboard logins. Prefer DISCOM lines over kWh hero metrics. Prefer kill criteria over indefinite pilots. Prefer truth about unknowns over false precision. Re-validate champion LinkedIn tenure the morning of outreach. Never commit without two bills. Never write to PLCs. Never expand scope mid-pilot because the champion is friendly — expand only after invoice proof.

12. Outreach sequencing memorandum

Week 0: confirm LinkedIn tenure and email pattern offline. Week 1: LinkedIn connect + short email; request two HT bills. Week 2: 20-minute call using cold-call bullets; map DISCOM lines. Week 3: send written 90-day scope with kill criteria and feeder sketch. Week 4-12: if contracted, weekly prescription cards and invoice checkpoints. If no reply after two touches, try secondary champion once, then park with a calendar reminder tied to a plant event (COD, season peak, audit close). Never pile four channels in 48 hours — it reads as spam. Keep WhatsApp for after a warm yes or phone capture. Log every objection in CRM using the objection table in section 4.4 so future agents do not repeat failed angles. When a champion forwards internally, ask who now owns the decision and restart discovery with that person rather than assuming prior context transferred cleanly.

13. Final residual checklist before first send

Confirm prospect_id matches kit filename. Confirm DISCOM token appears in section 2 (UPCL or UPPCL/PVVNL/Madhyanchal as applicable). Confirm the phrase The strongest wedge is: appears exactly once. Confirm section 6.1 lists controversies searched or none found with terms. Confirm champion email first backtick is syntactically valid. Confirm no Apollo notes were required. Confirm plant phone confidence tag in kit. Print two bills request into calendar follow-up. If any of the above fails, stop and edit before outreach site publish.